• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

KLF11 (Kru üppel-Like Factor 11) Inhibits Arterial Thrombosis via Suppression of Tissue Factor in the Vascular Wall.
Conclusions- Our data demonstrate that KLF11 is a novel transcriptional suppressor of F3 in vascular smooth muscle cells, constituting a potential molecular target for inhibition of arterial thrombosis. PMID: 30602303 [PubMed - as supplied by publisher]
Source: Arteriosclerosis, Thrombosis and Vascular Biology - January 3, 2019 Category: Cardiology Authors: Liang W, Fan Y, Lu H, Chang Z, Hu W, Sun J, Wang H, Zhu T, Wang J, Adili R, Garcia-Barrio MT, Holinstat M, Eitzman D, Zhang J, Chen YE Tags: Arterioscler Thromb Vasc Biol Source Type: research

Microglial-mediated PDGF-CC activation increases cerebrovascular permeability during ischemic stroke
AbstractTreatment of acute ischemic stroke with the thrombolytic tissue plasminogen activator (tPA) can significantly improve neurological outcomes; however, thrombolytic therapy is associated with an increased risk of intra-cerebral hemorrhage (ICH). Previously, we demonstrated that during stroke tPA acting on the parenchymal side of the neurovascular unit (NVU) can increase blood –brain barrier (BBB) permeability and ICH through activation of latent platelet-derived growth factor-CC (PDGF-CC) and signaling by the PDGF receptor-α (PDGFRα). However, in vitro, activation of PDGF-CC by tPA is very inefficient and the mec...
Source: Acta Neuropathologica - July 19, 2017 Category: Neurology Source Type: research

20 years of Modifying Stroke Risk in Sickle Cell Disease (SCD) Patients: a Single Center Experience of Bone Marrow Transplant (BMT) in SCD (P6.256)
Conclusions:While BMT is curative for SCD, the impact on cerebral vasculopathy and ongoing stroke risk is unknown. Data from this sample suggests that BMT is associated with stabilization but not resolution of vasculopathy and dramatic reduction of stroke after the first year.Study Supported by:N/ADisclosure: Dr. Carpenter has nothing to disclose. Dr. Farias Moeller has nothing to disclose. Dr. Abraham has nothing to disclose. Dr. Khademian has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Carpenter, J., Moeller, R. F., Abraham, A., Khademian, Z. Tags: Non-Atherosclerotic Angiopathies and Cerebral Venous Thrombosis Source Type: research

Endothelial Cell-Derived von Willebrand Factor Is the Major Determinant That Mediates von Willebrand Factor-Dependent Acute Ischemic Stroke by Promoting Postischemic Thrombo-Inflammation.
CONCLUSIONS: Plt-VWF, either in presence or absence of ADAMTS13, partially contributes to VWF-dependent injury and postischemic thrombo-inflammation after stroke. EC-VWF is the major determinant that mediates VWF-dependent ischemic stroke by promoting postischemic thrombo-inflammation. PMID: 27444201 [PubMed - as supplied by publisher]
Source: Arteriosclerosis, Thrombosis and Vascular Biology - July 20, 2016 Category: Cardiology Authors: Dhanesha N, Prakash P, Doddapattar P, Khanna I, Pollpeter MJ, Nayak MK, Staber JM, Chauhan AK Tags: Arterioscler Thromb Vasc Biol Source Type: research